BAWEI
837023
Yili Chuanning Biotechnology
301301
Shanghai Menon Animal Nutrition Technology
301156
4
Tongling Jieya Biologic Technology
301108
5
XI'AN WONDER
836419
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | ||||||||||
Goods sale service render cash | 320.21%95.3M | -7.05%274.53M | -11.88%178.78M | -29.23%98.43M | -52.81%22.68M | 35.76%295.36M | 53.20%202.88M | 136.95%139.08M | 217.31%48.06M | -36.12%217.55M |
Refunds of taxes and levies | ---- | --491.98K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash received relating to other operating activities | -13.86%1.62M | -0.95%5.34M | -18.58%5.87M | -12.12%4.95M | 11.41%1.89M | 18.83%5.39M | 17.56%7.21M | 27.56%5.63M | 5.13%1.69M | 13.95%4.53M |
Cash inflows from operating activities | 294.57%96.93M | -6.78%280.36M | -12.11%184.65M | -28.56%103.38M | -50.62%24.57M | 35.42%300.74M | 51.62%210.09M | 129.30%144.71M | 196.92%49.75M | -35.54%222.09M |
Goods services cash paid | 14.34%67.65M | -2.03%170.19M | -8.60%130.75M | 9.86%93.59M | 35.43%59.17M | 8.49%173.71M | 24.83%143.05M | 25.25%85.2M | 25.74%43.69M | -11.01%160.11M |
Staff behalf paid | 43.59%6.82M | 19.51%22.7M | 9.68%15.88M | 3.15%10.09M | 7.34%4.75M | -2.27%18.99M | -0.03%14.48M | -1.10%9.78M | -18.06%4.43M | -6.23%19.43M |
All taxes paid | 9.11%2.65M | 7.45%23.26M | -47.43%8.48M | -67.06%3.96M | -58.88%2.43M | 37.93%21.65M | 52.46%16.12M | 84.36%12.03M | 35.28%5.92M | -48.31%15.69M |
Cash paid relating to other operating activities | 30.05%5.58M | -27.47%19.76M | -26.19%12.26M | -15.84%9.16M | -18.84%4.29M | 23.59%27.25M | -0.03%16.61M | -14.02%10.88M | 2.01%5.29M | -10.72%22.05M |
Cash outflows from operating activities | 17.08%82.71M | -2.36%235.91M | -12.03%167.37M | -0.92%116.8M | 19.09%70.65M | 11.19%241.6M | 21.75%190.27M | 21.42%117.88M | 19.34%59.32M | -15.03%217.29M |
Net cash flows from operating activities | 130.85%14.22M | -24.84%44.45M | -12.81%17.29M | -150.03%-13.42M | -381.52%-46.08M | 1,132.74%59.14M | 211.96%19.83M | 178.93%26.82M | 70.96%-9.57M | -94.60%4.8M |
Investing cash flow | ||||||||||
Cash received from disposal of investments | ---- | --19.25M | --20M | --20M | ---- | ---- | ---- | ---- | ---- | ---- |
Cash received from returns on investments | ---- | --895.92K | --147.74K | --147.74K | ---- | ---- | ---- | ---- | ---- | 25.05%953.59K |
Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | ---- | -96.31%130.39K | -96.22%130.39K | -95.26%130.39K | 339.89%32.77K | 2,327.40%3.54M | 5,887.22%3.45M | 13,888.16%2.75M | --7.45K | -99.51%145.68K |
Cash inflows from investing activities | ---- | 473.43%20.28M | 487.17%20.28M | 636.54%20.28M | 339.89%32.77K | 221.69%3.54M | 5,887.22%3.45M | 13,888.16%2.75M | --7.45K | -96.41%1.1M |
Cash paid to acquire fixed assets intangible assets and other long-term assets | -47.14%2.06M | -50.97%18.44M | -57.92%13.2M | -52.94%7.77M | -53.29%3.9M | 20.23%37.61M | 92.10%31.38M | 85.36%16.52M | -26.83%8.35M | 47.39%31.28M |
Cash paid to acquire investments | ---- | --20M | --20M | --20M | --20M | ---- | ---- | ---- | ---- | ---- |
Cash outflows from investing activities | -91.37%2.06M | 2.21%38.44M | 5.81%33.2M | 68.14%27.77M | 186.09%23.9M | 20.23%37.61M | 92.10%31.38M | 85.36%16.52M | -26.83%8.35M | 47.39%31.28M |
Net cash flows from investing activities | 91.36%-2.06M | 46.70%-18.16M | 53.72%-12.92M | 45.55%-7.49M | -185.96%-23.87M | -12.89%-34.07M | -71.57%-27.93M | -54.81%-13.76M | 26.90%-8.35M | -420.19%-30.18M |
Financing cash flow | ||||||||||
Cash received from capital contributions | ---- | --2.25M | --2.25M | --1.5M | ---- | ---- | ---- | ---- | ---- | ---- |
-Including: Cash received from capital contributions by minority shareholders of subsidiaries | ---- | --2.25M | --2.25M | --1.5M | ---- | ---- | ---- | ---- | ---- | ---- |
Cash inflows from financing activities | ---- | --2.25M | --2.25M | --1.5M | ---- | ---- | ---- | ---- | ---- | ---- |
Cash payments relating to other financing activities | -37.06%106.73K | 14,195.32%26.93M | 19,027.77%27.03M | 95.97%153.83K | 260.06%169.59K | 20.00%188.4K | 12.50%141.3K | 0.00%78.5K | 50.00%47.1K | 900.00%157K |
Cash outflows from financing activities | -37.06%106.73K | 14,195.32%26.93M | 19,027.77%27.03M | 95.97%153.83K | 260.06%169.59K | 20.00%188.4K | 12.50%141.3K | 0.00%78.5K | 50.00%47.1K | -97.91%157K |
Net cash flows from financing activities | 37.06%-106.73K | -13,001.05%-24.68M | -17,435.42%-24.78M | 1,814.86%1.35M | -260.06%-169.59K | -20.00%-188.4K | -12.50%-141.3K | 0.00%-78.5K | -50.00%-47.1K | 97.91%-157K |
Net cash flow | ||||||||||
Net increase in cash and cash equivalents | 117.18%12.05M | -93.52%1.61M | -147.74%-20.42M | -250.74%-19.57M | -290.33%-70.12M | 197.44%24.89M | 75.84%-8.24M | 130.22%12.98M | 59.54%-17.96M | -128.14%-25.54M |
Add:Begin period cash and cash equivalents | 0.50%323.14M | 8.39%321.53M | 8.39%321.53M | 8.39%321.53M | 8.39%321.53M | -7.93%296.65M | -7.93%296.65M | -7.93%296.65M | -7.93%296.65M | 39.22%322.18M |
End period cash equivalent | 33.32%335.19M | 0.50%323.14M | 4.41%301.11M | -2.48%301.96M | -9.79%251.41M | 8.39%321.53M | 0.11%288.4M | 10.89%309.63M | 0.32%278.68M | -7.93%296.65M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | Zhonghua Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhonghua Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhonghua Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.